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Abstract
The effects of Glucosamine Sulphate (GS) and Chondroitin
Sulphate (CS) on the healing of damaged and repaired
articular cartilage were investigated. This study was
conducted using 18 New Zealand white rabbits as
experimental models. Focal cartilage defects, surgically
created in the medial femoral condyle, were either treated
by means of autologous chondrocyte implantation (ACI)
or left untreated as controls. Rabbits were then divided into
groups which received either GS+/-CS or no
pharmacotherapy. Three rabbits from each group were
sacrificed at 12 and 24 weeks post-surgery. Knees dissected
from rabbits were then evaluated using gross quantification
of repair tissue, glycosaminoglycan (GAG) assays,
immunoassays and histological assessments. It was
observed that, in contrast to untreated sites, surfaces of the
ACI-repaired sites appeared smooth and continuous with
the surrounding native cartilage. Histological examination
demonstrated a typical hyaline cartilage structure; with
proteoglycans, type II collagen and GAGs being highly
expressed in repair areas. The improved regeneration of
these repair sites was also noted to be significant over time
(6 months vs. 3 months) and in GS and GS+CS groups
compared to the untreated (without pharmacotherapy)
group. Combination of ACI and pharmacotherapy (with
glucosamine sulphate alone/ or with chondroitin sulphate)
may prove beneficial for healing of damaged cartilage,
particularly in relation to focal cartilage defects.
Keywords: Animal models, cartilage repair, chondrocytes,
collagens, proteoglycans
*Address for correspondence:
Sharaniza Ab-Rahim
Faculty of Medicine, University of Technology MARA
Level 20, Tower 2 S&T Complex
Shah Alam Selangor 40450
Malaysia
E-mail: sharaniza_abrahim@yahoo.com
Introduction
Traumatic articular cartilage injuries of the knee, as a result
of acute and repetitive impact loading or rotational force
of the joint surface, contribute up to 50% (Piasecki et al.,
2003; Shelbourne et al., 2003) of all cartilage related
diseases. Although there have been reports of limited
spontaneous repair in damaged cartilage, these defects
generally do not undergo complete repair (Piasecki et al.,
2003; Shelbourne et al., 2003; Davis and Jones, 2004).
To improve the healing process, a number of orthopaedic
surgical procedures, including sub-chondral drilling,
abrading and microfracture have been previously
introduced. All of these techniques claim to promote
hyaline (or at least hyaline-like) cartilage repair
(O’Driscoll, 1998; Bentley et al., 2003; Shelbourne et al.,
2003). However, long-term studies have demonstrated that
these techniques only produce modest clinical outcomes,
with many of the repaired sites filled with
fibrocartilaginous tissue (Erggelet et al., 2003; Horas et
al., 2003; Steadman et al., 2003a; Steadman et al., 2003b).
These fibrocartilage tissues delaminate hyaline articular
cartilage during motion, causing irreversible damage to
the opposing joint surface (Kim et al., 1991; O’Driscoll,
1998; Wang, 2002; Erggelet et al., 2003; Steadman et al.,
2003a; Steadman et al., 2003b). Alternative means of
cartilage repair by transplanting hyaline cartilage from
unaffected sites have also met with limited success due to
a variety of reasons. These include restricted amounts of
cartilage available from donor sites, donor site morbidity,
and incongruity of the repaired joint surfaces (O’Driscoll,
1998; Wang, 2002; Horas et al., 2003).
In response to these limitations, Brittberg and co-
researchers (1994) introduced autologous chondrocyte
transplantation (ACT) or autologous chondrocyte
implantation (ACI), which employs tissue engineering
concepts to promote biological repair in focal cartilage
defects (Bentley et al., 2003; Erggelet et al., 2003; Wada
et al., 2003; Yates, 2003). In addition to promoting
restoration of larger defects, ACT has been shown to
induce hyaline-like tissue regeneration (Brittberg et al.,
1994; Brittberg, 1999; Brittberg et al., 2001). However,
this method has inherent limitations, among which is the
prolonged recovery period required before the repair sites
are able to tolerate normal joint stresses. To overcome
this problem, current studies focus on stepping up tissue
healing by (1) introducing cell scaffolds that provide the
biomechanical strength needed to withstand early
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exposure to joint stresses, or by (2) enhancing tissue
differentiation through growth factor-induced cellular
expression (Miura et al., 1994; Brittberg, 1999; Brittberg
et al., 2001; Brittberg, 2008). Although the role of
stimulating factors and hormones to increase phenotypic
cell expression has been well established in various in vitro
models, their clinical applications have not been as
forthcoming (Miura et al., 1994; Mercy Tissue
Engineering, 2002; Brittberg, 2008).
Glucosamine sulphate (GS) and chondroitin sulphate
(CS) are two most frequently prescribed nutritional
supplements for the treatment of osteoarthritis (Noack et
al., 1994; Matheson and Perry, 2003; Richy et al., 2003),
yet controversy surrounds their efficacy and definitive
mechanism of action. In the extensive multicentre GAIT
study (Sawitzke et al., 2009), GS combined with CS
appeared to provide significant pain relief but only in the
‘moderate-to-severe pain’ subset of osteoarthritic patients.
Indeed, these pharmacotherapies have not been indicated
for focal cartilage lesions, nor have they been proven to
benefit patients who have undergone cartilage repair
procedures. In an attempt to establish the roles of these
drugs for the aforementioned conditions, a study was
conducted to determine the effects of glucosamine sulphate
with/without chondroitin sulphate on (1) untreated focal
damaged cartilage and, (2) cartilage which was repaired
using ACI. The findings of this study would be helpful to
ascertain the roles of these dietary supplements in the repair
of traumatic focal cartilage defects or in accelerating the
healing rate of ACI surgically repaired cartilage.
Materials and Methods
Eighteen (N=18) male New Zealand white rabbits aged
between 14 to 16 weeks, weighing approximately 3.5±1
kg were used in this study (involving a total of 36 knee
joints). The study conformed strictly to University
regulations on animal experimentation, and was approved
by the University of Malaya Animal Ethics Review Board
(approval reference: OS/06/07/08/TKZ/A(R)).
Rabbits were randomly divided into 3 groups with 6
rabbits in each group (n=6); Group 1 (without GS and CS/
control), Group 2 (GS) and Group 3 (GS + CS). A defect
was created on both knee joints of each rabbit (36 knee
joints). Implantation was carried out on the right knees of
each rabbit after 3 weeks of defect creation. Three rabbits
from each group were sacrificed at 3 months and another
3 rabbits from each group were sacrificed at 6 months post-
implantation.
Preoperative procedures and biopsy of articular
cartilage
Prior to surgery, the rabbits were anaesthetized with
intravenous sodium pentobarbital (Rhone Merieux Ltd.,
Essex, UK). A preoperative dose of cefazolin (33 mg/kg)
was given intravenously. Using a custom made
chondrotome, a circular cartilage defect (measuring 5 mm
width x approximately 2 mm depth) was created on the
medial femoral condyle of each hind knee joint. The
cartilage within the demarcated area was completely
removed using a size 11 blade whilst maintaining the
integrity of subchondral bone. Cartilage samples were sent
immediately for cell (chondrocyte) culture in dedicated
clean labs. The wound was surgically closed in layers using
absorbable sutures (daxon 5/0).
Chondrocyte culture
Chondrocyte extraction was performed using a modified
chondrocyte culture technique established previously
(Kamarul et al., 2008). Finely minced cartilage tissues were
digested overnight using Type II collagenase (0.6%). Cells
released from the tissue were then centrifuged at 1200 rpm
prior to culture in DMEM/F-12 (1:1) media, supplemented
with 10% foetal bovine serum (FBS) at a seeding density
of 1x105 cells/ml (and at 5% CO2). After reaching
confluence, dissociation with trypsin-EDTA was carried
out prior to suspension of chondrocytes in 1.2% sodium
alginate at a density of 10 x 106 cells/ml. Calcium alginate
beads were formed by exposing drops of the cell
suspension to 50 mM calcium chloride for 10 min. Newly
formed beads were removed from the calcium chloride
solution, rinsed with normal saline and placed onto cell
culture plates and covered with culture medium.
Implantation of chondrocyte-alginate constructs
In the second stage of the procedure, repair of the rabbit
right knee, was performed after 3 weeks to mimic
conditions of an early repair. A periosteal flap of 7 mm
diameter was harvested from the medial aspect of the
proximal tibia of the same hind limb. The flap was then
placed on top of the articular cartilage defect with the
cambium layer facing the defect and anchored using 8-0
Vicryl absorbable sutures at intervals of 2-3 mm with the
knots concealed beneath. A superior opening was left for
placement of the chondrocytes. In vivo chondrocyte-
alginate transplantation was performed as described by
Mierisch et al. (2003). However, a slight modification was
employed in this study. Two calcium alginate beads
containing autologous chondrocytes (approximately 5 x
104 cells/bead) acquired from the same rabbits were placed
into the defective sites underneath the periosteal covering.
The superior opening of the periosteal flap was sutured
followed by wound closure using absorbable sutures
(daxon 5/0).
Gavage
Gavage was carried out via insertion of a nasogastric tube
(size 14) into the rabbit oesophagus (20 cm from the mouth
orifice) to ensure the drugs were fully administered.
Rabbits in Group 1 were gavaged with normal saline
(Control Group), Group 2 was gavaged with 120 mg/day
glucosamine sulphate (GS Group), and Group 3 was
gavaged with 120 mg/day glucosamine sulphate and 100
mg/day chondroitin sulphate (GS + CS Group). These
drugs were administered daily until the time of sacrifice.
The doses in rabbits were calculated on the basis of
the usual recommended doses in humans as previously
described (Tiraloche et al., 2005; Herrero-Beaumont et
al., 2008). Normal human consumption is 1500 mg/day
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of GS and 1200 mg/day for CS therefore, approximately
about 21.5 mg/kg/day of GS and 17 mg/kg/day were given
daily for 5 kg rabbit.
Sacrifice
Three (n=3) rabbits from each treatment group were
sacrificed at 12 and 24 weeks after chondrocyte
transplantation respectively. Rabbits were sacrificed by
intravenous sodium pentobarbitone overdose. Both femurs
were dissected proximally by disarticulating the hip joint,
after which the medial femoral condyle was then separated
by transecting the femur at the supracondylar region.
Macroscopic evaluation (using the Brittberg/ICRS visual
histological assessment) (Mainil-Varlet et al., 2003)
followed by histological analysis (using modified
O’Driscoll/ICRS histological grading) (O’Driscoll et al.,
1988; Mainil-Varlet et al., 2003) and sulphated
glycosaminoglycan (S-GAG) assay were performed.
Biochemical assay for glycosaminoglycans
Each specimen (area of created defect) was cut into two.
One half of the specimen was dissected into small pieces
using a scalpel prior to digestion. Enzymatic digestion was
achieved by using Radio-immunoprecipitation Assay
(RIPA) buffer (1 ml) supplemented with protease inhibitor
for 1 h. The buffer was used to extract total protein from
the cells to determine total protein content of the specimen
enabling correction or normalisation of the GAG level in
each sample. The cell lysate was divided into two, 900μl
used for Glycosaminoglycan (GAG) and 100 l for protein
content determination using a BlyscanTM Assay Kit
(Bicolor, Belfast, Northern Ireland) (Farndale et al., 1986)
and Bio-Rad (Hercules, CA, USA) DC® Protein Assay
(Kamarul et al., 2008), respectively. Absorbance was read
at 656 nm (for GAG) and at 750 nm (for protein)
wavelength using spectrophotometry and compared to a
standard plot derived from shark chondroitin sulphate to
determine the GAG content. The level of GAG (g) in
each mg protein was then measured following the
manufacturer’s recommendation.
Histological examination
The second half of the specimen was used for histological
assessment. Similar joint specimens were fixed in 10%
phosphate-buffered formalin (4% formaldehyde) for at
least 24 h, followed by decalcification and embedding in
Figure 1: Examples of gross appearances of the knee articular cartilage on the femoral side of an adult New
Zealand White rabbit (Group 3). Plate (a) demonstrating the defect created on the right knee before implantation
(red circle); (b) right knee (repaired) at 3 months post-implantation showing completely filled defect covered with
regenerated cartilage surface (red circle); (c) left (unrepaired) knee of the same rabbit showing defect filled with
non-shiny/denuded irregular cartilage surface (red circle). In comparison to rabbits at 6 months, (d) the damage in
the right knee (repaired) demonstrated almost complete healing with minimal cartilage defect visible.
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paraffin such that 5m thick sections could be cut. Using
standard histochemical techniques, histological sections
were stained with Haematoxylin & Eosin (H&E) and
Safranin-O. Immunostaining for type II collagen was
performed on histological sections following the
manufacturer’s instructions (DAKO® TBS) and using a
mouse monoclonal primary antibody against type II
collagen (Calbiochem, Germany) with specificity to
human, rabbit, rat and bovine tendon/cartilage (Kivirikko,
1993).
Statistical analysis
The mean Brittberg score (i.e., a modification from the
ICRS Cartilage Injury Evaluation Package
[www.cartilage.org]) (Peterson et al., 2000; Mainil-Varlet
et al., 2003), modified O’Driscoll scores (O’Driscoll et
al., 1988), histological scores and GAG (Farndale et al.,
1986) levels were calculated from samples of both knees
(n=36). Inter- and intra-group differences were analysed
using non-parametric tests, including Kruskal-Wallis and
Mann-Whitney U tests. The statistical package software
SPSS (version 13.0) was used for the analyses with
statistical significance set at 5% (p0.05).
Results
Assessment was carried out to compare the effects of
pharmacotherapy between groups; Group 1 (without GS
and CS i.e. control), Group 2 (GS) and Group 3 (GS +
CS). Effects of surgical intervention, ACI repaired site
(right knee) and unrepaired site (left knee) of each group
to the pharmacotherapy treated rabbits were also assessed.
Gross morphological analysis
The defect sites in the untreated (left) knees of all 3 groups
demonstrated minimal repair with uneven and irregular
surfaces noted. These defects appeared to be filled with
whitish regenerative tissue denoting ongoing repair. In ACI
treated sites (right knees) of Groups 2 and 3, the
regenerative tissue appeared thicker than in Group 1 and
more closely resembled the adjacent articular cartilage (Fig.
Groups 
Brittberg Scores 
Right Knee Left Knee 
12 weeks (n=3) 24 weeks (n=3) 12 weeks (n=3) 24 weeks (n=3) 
Group1; No 
Pharmacotherapy 
4.67±0.58 
(3.2-6.1) 
5.00 ± 0.00 
(n.a) 
0.00 ±0.00 
(n.a) 
1.67 ±0.58 
(0.2-3.1) 
Group 2; GS 6.33* ±0.58 (4.9-7.8) 
8.33* ±0.58 
(6.9-9.8) 
2.33 ±0.58 
(0.9-3.8) 
3.00 ±0.00 
(n.a) 
Group 3; GS + CS 7.00*±1.00 (4.5-9.5) 
8.33*±1.53 
(4.5-12.1) 
3.33±0.58 
(1.9-4.8) 
3.33±0.58 
(1.9-4.8) 
Groups 
GAG values in μg/mg protein  
Right Knee Left Knee 
12 weeks (n=3) 24 weeks (n=3) 12 weeks (n=3) 24 weeks (n=3) 
Group1; No 
Pharmacotherapy 
0.84 ±0.17 
(0.4-1.3) 
1.37 ±0.53 
(0.1-2.7) 
0.78±0.19 
(0.3-1.2) 
0.84 ±0.34 
(0.0-1.7) 
Group 2; GS 1.02 ±0.12 (0.7-1.3) 
2.72*±0.78 
(0.8-4.6) 
0.76±0.11 
(0.5-1.0) 
1.50 ±0.45 
(0.4-2.6) 
Group 3; GS + CS 1.49 ±0.74 (0.3-3.3) 
3.25* ±0.29 
(2.5-4.0) 
0.88±0.24 
(0.3-1.5) 
1.89 ±0.43 
(0.8-2.9) 
Groups 
Modified O’Driscoll scores  
Right Knee Left Knee 
12 weeks (n=3) 24 weeks (n=3) 12 weeks (n=3) 24 weeks (n=3) 
Group1; No 
Pharmacotherapy 
8.67 ±3.79 
(0.7-18.1) 
10.00 ±3.00 
(2.5-17.4) 
5.67 ±1.53 
(1.9-9.5) 
3.67 ±1.16 
(0.8-6.5) 
Group 2; GS 14.33* ±6.11 (0.8-29.5) 
14.67*±2.52 
(8.4-20.9) 
8.00 ±5.29 
(5.1-21.1) 
7.67 ±4.73 
(4.1-19.4) 
Group 3; GS + CS 14.67* ±5.03 (0.8-27.2) 
18.67*±1.53 
(14.9-22.5) 
8.00 ±6.56 
(8.3-24.3) 
7.33 ±5.51 
(6.3-21.0) 
Table 1: Mean values of the Brittberg, Modified O’Driscoll score and GAG quantification of the repaired cartilage
comparing the different groups at different times of analysis. Values are mean ± standard deviation (SD) and 95%
confidence intervals in parentheses.
n.a – not available.
* P<0.05 when compared with Group 1 at the respective time point.
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1). Although some areas showed mild central depressions
in these repair sites, this tissue appeared to be mostly
smooth and integrated with the surrounding cartilage with
no apparent demarcating borders. No periosteal thickening
was seen in any of the ACI treated sites.
Significant differences in the mean Brittberg scores
between the different pharmacological groups (Group 2
and 3) were noted when knees of the respective sides were
compared. Differences in the mean Brittberg scores in the
right knee were found to be significant when comparison
were made between the control group (Group 1) and those
receiving oral pharmacotherapy at 12 weeks i.e. Groups 1
vs. 2 and Groups 1 vs. 3 (Mann Whitney-U test: p=0.04
and p=0.03 respectively). Similar p values at were also
observed when comparison were made between groups 1
(control group) and 2 (p=0.04); and between groups 1 and
3 (p=0.03) at 24 weeks. In Group 1, the mean Brittberg
grading scores (Table 1) were 5-fold (at 3 months) and 3-
Figure 2: Haematoxylin and Eosin stained sections of the repaired sites in the different groups of adult New
Zealand White rabbit knee joints at 3 months post-implantation. Plate (a), (c) and (e) are images of the repaired
(right) knees according to the different groups (x4). Higher magnifications (x20) of these areas are illustrated in
plates (b), (d) and (f). Cell clustering with columnar cells arrangements can clearly be observed (as indicated by the
red circles) in plates (b), (d) and (f). The tide marks in cartilage tissue are indicated by the red arrows. Scale bars:
100 m.
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fold (at 6 months) higher in the implanted knees (right side)
than that of the non implanted left knees.
Histological analysis and cartilage repair score
In the ACI treated sites, hyaline cartilage repair was evident
in both H&E and Safranin-O stained sections at 3 and 6
months (Fig. 2, Fig. 3). At 12 weeks, chondrocytes appeared
in cluster formation with some columnar arrangements seen
in only group 3. The typical appearance of native cartilage
was lacking in all other groups. At 24 weeks however,
chondrocyte columns with substantial pericellular matrix
formation could be seen. There was intense staining of
Safranin-O noted on histological sections of the right knee,
indicating strong proteoglycan expression within the matrix
(Fig. 3). There was marked expression of type II collagen
in the implanted side, which appeared to be largely
homogenous with the surrounding native cartilage (Fig.
4). The untreated left knees showed contrasting
observations (Fig. 4).
Using the modified O’Driscoll scores (Table 2),
significant differences were observed between the ACI
treated (right) knees in the different groups (Kruskall-Wallis
test; p=0.026). However, no significant differences were
noted between the various groups in the untreated left
knees (Kruskall-Wallis test; p=0.53). The mean score
values for each group is summarized in Table 1. In the
control knees, there was little or no obvious repair tissue
or cell in-growth observed in the defective sites.
Histological examination demonstrated intense staining
with Safranin-O in ACI-treated sites in Group 3, indicating
that proteoglycans within the ECM were highly expressed.
Immunolocalisation of type II collagen showed
homogenous distribution of collagen in the implanted
knees, which was similar to the distribution pattern in
surrounding native articular cartilage. In Groups 2 and 3,
O’Driscoll scores (Table 1) demonstrated a 2-fold (at both
3 and 6 months) increase in chondrocyte-implanted knees
(right side) but were minimal (less than 1 fold increase) in
the untreated knees.
Biochemical analysis
Joint defects which underwent ACI (right knees) healed
significantly better than non-treated sites (left knees) in
all groups. Quantification of GAG deposition correlated
with histological assessment and also with increased type
II collagen expression seen on immunohistochemical
Figure 3: Photomicrograph of typical sections of Safranin-O stained knee joints of Group 1 adult New Zealand
White rabbit at 6 months post-implantation (a) Right knee (implanted) showing cartilage fill with proteoglycan
secreted extensively at the defect site; (b) Left knee (control) showing absence of repair at the defect site. Scale
bars: 100 m.
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staining. Such structural and biochemical evidence of
cartilage differentiation was progressively observed in
these repair sites and found to be significant over time i.e.
3 months vs. 6 months.
Between the pharmacological groups, significant
improvements were noted in the right knee between Group
1 to Groups 2 and 3 respectively (Mann Whitney U test:
p=0.047 in both groups) at 24 weeks post-implantation.
However, there were no significant differences between
groups 2 and 3 for GAG levels. Although some
improvement could be seen at 12 weeks when compared
to Group 1, these differences were not statistically
significant (Right knee: Group 2 p=0.18; Group 3, p=0.13.
Left knee: Group 2, p=1.0; Group 3, p=0.83). There were
also no differences between GAG depositions in the left
knees at 12 and 24 weeks (Please refer to Table 1).
Discussion
The use of autologous chondrocyte implantation (ACI) in
our study produced significant cartilage healing in
surgically created focal cartilage defects, as compared to
non-treated cartilage controls. The quality of cartilage
repair was further improved with administration of oral
glucosamine sulphate (GS) with/without chondroitin
sulphate (CS). Although the results of this study suggest
that GS/GS+CS pharmacotherapies may promote the
healing process in damaged and repaired articular cartilage,
it is worth noting that surgical repair through ACI is
required to elicit the significant healing when using these
drugs. The role of oral pharmacotherapy alone for the
treatment of non-repaired focal cartilage defects in this
study was not convincing.
At present, there are two available forms of
pharmacological preparations for the treatment of damaged
cartilage: (1) injectables, which act locally into the joints,
and (2) oral preparations, which act systemically. Intra-
articular injection, such as corticosteroids and hyaluronic
acid, have been suggested as treatments for articular
cartilage damage; however, the positive results seen in the
early stages of the therapy are usually short-lived. Oral
therapy, namely GS and CS (Lippiello, 2003), have been
claimed to be effective in stimulating articular cartilage
healing in patients with osteoarthritis. However, this
treatment has not been previously described for focal
cartilage damage. In the present study, the use of these
drugs appears to have a positive influence in the repair
process although the pathophysiological mechanisms
leading to repair remain unclear (Lippiello, 2003). In the
Figure 4: Photomicrographs of immunostained histological sections against type II collagen in the repaired (a) and
unrepaired (b) defect sites of Group 1 adult New Zealand White rabbit at 3 months post-implantation. Plate (a)
demonstrate an abundance in type-II collagen expression at the repaired site (right knee) while in Plate (b), there is
reduced type-II collagen expression within the defect site. Scale bars: 100 m.
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past, the roles of these supplements have been queried,
particularly in relation to whether direct metabolism can,
in effect, aid the increase in production of cartilage
proteoglycan sub-units (Laverty et al., 2005). Furthermore,
it is also unclear how oral GS and CS reach the defective
or repaired sites considering that cartilage itself is avascular
(O’Driscoll, 1998; Bentley et al., 2003; Piasecki et al.,
2003; Shelbourne et al., 2003). Although both drugs claim
to possess chondroprotective properties, only GS has been
widely described and studied in great detail (Noack et al.,
1994; Matheson and Perry, 2003; Richy et al., 2003;
Laverty et al., 2005). GS is an amino monosaccharide
precursor that is incorporated, either directly or after
conversion to galactosamine, into the disaccharide unit of
glycosaminoglycans (GAGs) located in proteoglycans
(PGs) of cartilage matrix (Mroz and Silbert, 2004).  Clinical
trials using GS for treating osteoarthritis have demonstrated
that this supplement provides symptomatic relief, although
slow acting (Noack et al., 1994; Matheson and Perry, 2003;
Richy et al., 2003). Conversely, other studies have shown
that GS produces no beneficial effect, possibly related to
the variable source of GS used (Reginster et al., 2001).
Based on lab experiments, synovial fluid
concentrations of GS are known to correlate with
Table 2: O’Driscoll histological and histochemical grading scale.
*Adapted from O’Driscoll et al., 1988.
 Score 
Nature of the predominant tissue 
   Cellular morphology 
                      Hyaline articular cartilage 
                      Incompletely differentiated mesenchyme 
                      Fibrous tissue or bone 
   Safranin-O staining of the matrix 
                      Normal or nearly normal 
                      Moderate 
                      Slight 
                      None 
 
 
4 
2 
0 
 
3 
2 
1 
0 
Structural characteristics 
   Surface regularity 
                      Smooth and intact 
                      Superficial horizontal lamination 
                      Fissures – 25-100% of the thickness 
                      Severe disruption, including fibrillation 
   Structural integrity 
                      Normal 
                      Slight disruption, including cysts 
                      Severe disintegration 
   Thickness 
                      100% of normal adjacent cartilage 
                      50-100% of normal cartilage 
                      0-50% of normal cartilage 
   Bonding to the adjacent cartilage 
                      Bonded at both ends of graft 
                      Bonded at one end, or partially at both ends 
                      Not bonded 
 
 
3 
2 
1 
0 
 
2 
1 
0 
 
2 
1 
0 
 
2 
1 
0 
Freedom from cellular changes of degeneration 
   Hypocellularity 
                      Normal cellularity 
                      Slight hypocellularity 
                      Moderate hypocellularity 
                      Severe hypocellularity 
   Chondrocyte clustering 
                      No clusters 
                      <25% of the cells 
                      25-100% of the cells 
 
 
3 
2 
1 
0 
 
2 
1 
0 
Freedom from degenerative changes in adjacent cartilage 
   Normal cellularity, no clusters, normal staining 
   Normal cellularity, mild clusters, moderate staining 
   Mild or moderate hypocellularity, slight staining 
   Severe hypocellularity, poor or no staining 
 
3 
2 
1 
0 
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peripheral blood concentrations when GS is introduced
intravenously or orally (Kim and Conrad, 1974; Setnikar
and Rovati, 2001). Furthermore, orally administered
radiolabelled glucosamine have been demonstrated to
reach the joints successfully and metabolised by
chondrocytes (Setnikar et al., 1984; Meulyzer et al., 2008).
On the other hand, GS/CS present in synovial fluids may
also be due to plasma ultrafiltration and cells at the
fenestrated capillaries or the synovial lining may be the
ones metabolising these drugs rather than chondrocytes
(Meulyzer et al., 2008). This may explain previous
observations by Laverty et al. that show only ~10%
increase of glucosamine concentration in synovial joint
fluid was found following intravenous (IV) or nasogastric
(NG) dosing as compared to serum concentrations
(Meulyzer et al., 2008). This bioavailability was deemed
to be insufficient to cause any improvement in cellular
expressions or metabolic activity as demonstrated by others
(Laverty et al., 2005; Meulyzer et al., 2008). For in vivo
effects of glucosamine on chondrocytes to be significant,
it has been demonstrated that the monosaccharide
component of GS would have to “accumulate” in cartilage
to levels at least 500 times higher than those present in the
synovial fluid of patients receiving therapeutic dosages
(Laverty et al., 2005; Meulyzer et al., 2008). This condition
is therefore unlikely to occur even in patients exposed to
prolonged use of GS (Reginster et al., 2001).
It has been postulated that GS may be preferentially
“targeting” cartilage tissue, which results in the positive
effect seen on cartilage homeostasis (Setnikar and Rovati,
2001; Meulyzer et al., 2008). Another possible reason may
be due to the fact that GS provides improved metabolism
in tissues other than articular joints (such as intestine, liver
and potentially kidney) and thus, indirectly improves the
function of chondrocytes (Setnikar and Rovati, 2001). This
finding has been substantiated by a number of experiments
in many independent laboratories, which have not
uncovered any high-affinity binding partners for
glucosamine in cartilage. It has been suggested instead
that glucosamine behaves much like other freely diffusible
nutrients (Kim and Conrad, 1974; Morales and Hascall,
1989; Noyszewski, 2001). Having noted the high serum
levels of GS, this theory seems plausible as many
glucosamine-mediated effects on cells (Dodge and
Jimenez, 2003) are thought to be related to its known
stimulation (as glucosamine-6-phosphate [GlcN6P]) of the
intracellular hexosamine biosynthetic pathway (HBP)
(Rumberger et al., 2003).
In comparison, CS is said to produce superior
therapeutic effects than GS, although there have not been
any large clinical studies that directly compares the effects
of these two drugs (Das and Hamam, 2000; Dechant et
al., 2005). More interestingly, there are also very few
studies that describe the efficacy of a drug combination
(i.e., GS-CS) in improving cartilage repair processes (Chan
et al., 2005). The findings of our study appear to
complement previous clinical studies in animals and in
vitro conditions, demonstrating that: (1) combined therapy
has been shown to have protective and beneficial effects
in vitro by acting synergistically in stimulating the
production of PGs in articular cartilage, while inhibiting
the activity of the degradative enzymes (Dechant et al.,
2005), and (2) in studies involving animal models, this
combination is shown to exert a protective effect on
cartilage degradation (Bassleer et al., 1998; Chan et al.,
2005). However, these findings are not consistently
supported by others, with many reports showing mixed
results (Lipeela et al., 2000; Orth et al., 2002; Dodge and
Jimenez, 2003; Ilic et al., 2003; Lippiello, 2003; Persiani
et al., 2004). In one study involving 12 human subjects, it
was even reported that the administration of a combination
of these drugs lead to the reduction of GS bioavailability
in plasma (Lipeela et al., 2000). It is interesting to note
that others have shown combining GS with CS yields a
synergistic rather than additive effect (Hungerford, 1998;
Sandy et al., 1998) (which is clearly demonstrated in our
own study).
Using young rabbits for the implantation work
however, has its own limitations. The possibility of an age-
related wound healing process in articular cartilage may
have influenced the results in this study. However, although
rabbits that were not fully matured (14 to 16 weeks) were
utilised for this work, their age was close to that of maturity
(20 weeks). In addition, post-implantation healing was
analysed at 3 and 6 months, by which time these rabbits
had clearly reached maturity (>20 weeks).
Based on the results of our study and that reported by
others (Homandberg et al., 2006), it is valid to say that
there may be a functional role for glucosamine (GS) and
chondroitin sulphate (CS) in the repair process of damaged
cartilage. It is also evident that by supplementing rabbits
with GS and CS, there were significant improvements to
cartilage regeneration, although adding CS to subjects
already receiving GS did not appear to provide significant
improvements. In the clinical setting, we therefore advocate
glucosamine sulphate be considered as a possible adjunct
treatment to patients undergoing autologous chondrocyte
implantation (ACI), as the effect of these supplements in
enhancing joint repair processes appears to be promising
(this is a novel finding). For future protocols involving
rehabilitation of patients undergoing ACI, incorporation
of GS (and even CS) either peri-operatively and/or post-
operatively may need to be seriously considered in order
to optimise cartilage repair, and thus reduce the recovery
time for these patients. However, further study involving
a larger sample population may be needed to confirm
definitively the role of these nutrition supplements on
cartilage repair.
Conclusions
In summary, based on the gross (Brittberg score),
histological (O’Driscoll score) and biochemical  (GAG
content) analyses of autologous chondrocyte implantation
treated sites, both glucosamine sulphate alone or with
chondroitin sulphate produced statistically significant
improvements in cartilage regeneration. However, surgical
intervention through ACI, appears to be still necessary for
damaged cartilage to undertake significant tissue repair.
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The use of oral pharmacotherapy especially glucosamine,
may assist in improving the cartilage repair process,
although the addition of CS to GS supplementation may
not provide further advantage. Although further study is
warranted, combination of ACI and pharmacotherapy may
prove beneficial for healing of damaged cartilage,
particularly in relation to focal cartilage defects.
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Discussion with Reviewers
Reviewer I: Surely the glucosamine sulphate is affected
by the hydrochloride in the stomach? Can it then reach the
circulation? Was the hydrochloride salt used in the other
studies quoted?
Authors: A pharmacokinetic study (Setnikar et al., 1986,
text reference) has shown that after oral administration of
glucosamine sulphate, it is rapidly broken down to
glucosamine and sulphate. The sulphate will be ionised
completely in the stomach’s hydrochloric acid and released
to the blood stream. This dissociation will make all the
glucosamine available for absorption to the small intestine.
Once absorbed into the blood stream, glucosamine, which
is independent of the original salt, becomes available to
the body (Web ref, 1).
Reviewer I: Should the hydrochloride be given?
Authors: Glucosamine is also available as glucosamine
hydrochloride and has been used widely even though there
are limited studies of glucosamine HCl in humans (Fox
and Stephens, 2007). Both salts (hydrochloride and
sulphate), in their pure form, deliver equally effective
amounts of the desired glucosamine to joint cartilage. This
is because they will be broken down in the stomach’s
hydrochloric acid. Whereas in terms of bioavailability of
glucosamine, a previous study (Setnikar et al., 1986; Web
Ref. 1) has shown that 54% of the glucosamine that moves
into the small intestine (pH 6.8) exists in its un-ionised
form while 46% is in ionised form (the amine group is
protonated and positively charged). In the blood (pH 7.4)
75% of the glucosamine is present as the neutral amine
while only 25% is ionised. Since ionisation or high polarity
is an obstacle in crossing cellular membranes, the ability
of glucosamine to exist predominantly in its less polar (un-
ionised) form in the small intestine and even more in the
blood contributes directly to its bioavailability. Therefore,
the specific salt form is relevant only as a convenient
delivery vehicle for glucosamine provided that the salt must
readily dissolve in stomach acid (HCl) when ingested.
Preference between these 2 forms is normally based on
their relative purity and economics.
Reviewer I: Do you accept that the defect is not chronic?
Authors: While we do agree that the defect is not chronic,
we could not describe it as being acute either. A lapse of 3
weeks from the time of injury to the time of repair was
observed. Even in humans, this will not be considered acute
let alone in rabbits. We could classify it as being sub-acute.
Even then this would not be easy to be categorized as such
as this may not be applicable in rabbits. Other models
describing similar techniques have been described
(Mierisch et al., 2003, text reference), who have made
similar assumptions of the suitability for the time of repair
using comparable models.
Reviewer I: Do you accept that using an alginate bead is
not standard ACI?
Authors: Yes, we accept that alginate bead is not standard
practice but it was practical in this study. It is also an
accepted technique published elsewhere (Mierisch et al.,
2003, text reference).
Reviewer II: Is the absorption of GS and CS by rabbits
similar to humans? Are there studies to show this?
Authors: As far as we are aware, no studies have been
carried out that have compared the absorption rates of both
these compounds or have made direct comparison of the
absorption rate in humans and rabbits.
Reviewer II: Was there any attempt made to show that
GS and CS levels were increased in the synovial fluid of
the rabbit knees?
Authors: This experiment was not conducted as it was
outside the scope of this study. Furthermore this idea was
not formulated as part of the research hypothesis owing to
the knowledge that previous studies have demonstrated
that an increase in the glucosamine concentration after the
ingestion of GS and CS is definite. However, it has been
argued that the levels seen the knee synovial fluid are
insufficient to be compared to the effects observed in in
vitro models. Regardless of these findings, it was clear in
this study that the use of GS and CS had a definite positive
effect on the repair of damaged and repair cartilage.
Reviewer II: Studies on cartilage healing in a rabbit model
generally gives good results. Can the good results be
extrapolated to humans without validation with a similar
study in a larger animal, e.g., sheep or pig?
Authors: The rabbit has been accepted as a standard
animal model in articular cartilage studies. The authors do
not see any problem in extrapolating good results to human
as this has been practiced in previous studies (Brittberg et
al., 1996; O’Driscoll et al., 1988, text reference). This is
taking into consideration the translational model conducted
by Brittberg and Petterson using the rabbit as their ACI
model before use in humans.
Reviewer III: Regarding Fig. 2, the repair cartilage tissue
is very thin and one may argue that it could also be residual
tissue of the articular cartilage, left behind after the defect
was created. It would therefore be appropriate to show the
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histology of a fresh defect as well as a defect three weeks
later, just prior to chondrocyte transplantation.
Authors: We agree with the reviewer that histological
studies of the fresh defect prior to chondrocyte
transplantation would be appropriate. However, in practice,
this is impossible to conduct as there will be a need to
sacrifice the rabbit in order to do the histological study of
the defective site prior to transplantation of the rabbit. In
this study, we did compare the left knee (unrepaired) to
the right knee (implanted) of the same rabbit, thereby
demonstrating that the rate and quality of healing were
dissimilar between the treated and untreated knees. To
ensure that there was no residual tissue left within the defect
site at the end of the first surgery, care was taken to remove
all possible tissues while ensuring that the subchondral
bone was not breeched.
Reviewer III:: From Fig. 2 it appears that in ACI-treated
knee joints there is a very thin repair cartilage tissue with
possible advancement of the bone front. The repair process
may be endochondral ossification ultimately leading to loss
of articular cartilage. Please comment!
Authors: While this may be the case when observed with
the naked eye, our histological sections have proven
otherwise. This finding was confirmed by our independent
histologists who have also provided us with the grading to
demonstrate the quality of the cartilage tissue.
Reviewer III: It may be that GS/CS treatment may affect
durability of the repair cartilage tissue. Do the authors have
data at longer time points to assess durability?
Authors: We agree that time points we have used (3
months and 6 months) are short as compared to other
studies in which rabbits were sacrificed at 2 year post-
transplantation. This is part of the limitation of this study.
Therefore, we have used younger animals in this study,
which we believe will provide a more rapid response and
therefore demonstrate better the effect of the surgical
intervention in the pharmacotherapy treatment. We foresaw
that this may have inherent problems giving a false
impression of the repair even in the untreated site. To
circumvent this problem, we proceeded in creating defects
in both knees, but only repaired one knee and leaving the
other knee as control. The control site provided the
comparative data that demonstrates the rate at which
natural repair will take place if the knee is left untreated.
This study shows that almost no spontaneous improvement
of the defective sites occurred during the repair process so
that spontaneous healing in defective sites of young(-ish)
rabbits is not a problem in this study.
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